3-异丁基-1-甲基黄嘌呤(IBMX) - CAS:28822-58-4 - CAS号查询_生物试剂_化学试剂_分析试剂

中文名称:	3-异丁基-1-甲基黄嘌呤(IBMX) 促销
英文名称:	3-Isobutyl-1-methylxanthine
别名:	3-异丁基-1-甲基黄嘌呤 IBMX
CAS No:	28822-58-4	分子式:	C₁₀H₁₄N₄O₂	分子量:	222.24
CAS No:	28822-58-4
分子式:	C₁₀H₁₄N₄O₂
分子量:	222.24
MDL:	MFCD00005584	EINEC:	249-259-3
EINEC:	249-259-3

安全技术说明书(PDF) MSDS(PDF) 点击下载产品说明书(PDF) 点击下载技术规格说明书(PDF)

I70005 3-异丁基-1-甲基黄嘌呤(IBMX) ≥99%(HPLC) (psaitong)

相关产品

2'，3'-cGAMP钠盐
CAS No：1441190-66-4
半胆碱-3
CAS No：312-45-8
1,2-双(2-氨基苯氧基)乙烷-N,N,N',N'-四乙酸四乙酯
CAS No：73630-07-6
BAPTA 四钾盐
CAS No：73630-08-7
BAPTA 四甲酯
CAS No：125367-34-2
吩嗪硫酸乙酯
CAS No：10510-77-7

熔点：

200-201°C

外观与性状：

白色絮状粉末

包装规格：

100mg 250mg 1G in poly bottle

溶解性：

溶于DMSO(加热）和乙醇（10mg/ml)

产品描述：

基本信息

产品编号：	I70005
产品名称：	3-Isobutyl-1-methylxanthine
CAS:	28822-58-4	储存条件	粉末	-20℃	四年

分子式：	C10H14N4O2		溶于液体	-80℃	两年
分子量	222.24			-20℃	一个月
化学名：	3-isobutyl-1-methyl-3,9-dihydro-1H-purine-2,6-dione
Solubility (25°C)：
体外:	DMSO	44mg/mL (197.98mM)
	Ethanol	7mg/mL (31.49mM)
	Water	Insoluble
体内(现配现用):	1.请依序添加每种溶剂：10% DMSO→40% PEG300→5% Tween-80→45% saline Solubility: ≥ 1.67mg/mL (7.51mM); Clear solution
	此⽅案可获得 ≥ 1.67mg/mL (7.51mM，饱和度未知) 的澄清溶液。以 1mL ⼯作液为例，取 100μL 16.699999mg/mL 的澄清 DMSO 储备液加到 400μL PEG300 中，混合均匀；向上述体系中加⼊ 50μL Tween-80，混合均匀；然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。
	2.请依序添加每种溶剂：10% DMSO→90% (20% SBE-β-CD in saline) Solubility: 1.67mg/mL (7.51mM); Suspended solution; Need ultrasonic
	此⽅案可获得 1.67mg/mL (7.51mM) 的均匀悬浊液，悬浊液可⽤于⼝服和腹腔注射。以 1mL ⼯作液为例，取 100μL 16.699999mg/mL 的澄清 DMSO 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。
	3.请依序添加每种溶剂：10% DMSO→90% corn oil Solubility: ≥ 1.67mg/mL (7.51mM); Clear solution
	此⽅案可获得 ≥ 1.67mg/mL (7.51mM，饱和度未知) 的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以 1mL ⼯作液为例，取 100μL 16.699999mg/mL 的澄清 DMSO 储备液加到 900μL ⽟⽶油中，混合均匀。
	4.请依序添加每种溶剂：10% EtOH→40% PEG300→5%Tween-80→45% saline Solubility: ≥ 0.71mg/mL (3.19mM); Clear solution
	此⽅案可获得 ≥ 0.71mg/mL (3.19mM，饱和度未知) 的澄清溶液。以 1mL ⼯作液为例，取 100μL 7.1mg/mL 的澄清 EtOH 储备液加到 400μL PEG300 中，混合均匀；向上述体系中加⼊ 50μL Tween-80，混合均匀；然后继续加⼊ 450μL ⽣理盐⽔定容⾄ 1mL。
	5.请依序添加每种溶剂：10% EtOH→90% (20% SBE-β-CD in saline) Solubility: ≥ 0.71mg/mL (3.19mM); Clear solution
	此⽅案可获得 ≥ 0.71mg/mL (3.19mM，饱和度未知) 的澄清溶液。以 1mL ⼯作液为例，取 100μL 7.1mg/mL 的澄清 EtOH 储备液加到 900μL 20% 的 SBE-β-CD ⽣理盐⽔⽔溶液中，混合均匀。
	6.请依序添加每种溶剂：10% EtOH→90% corn oil Solubility: ≥ 0.71mg/mL (3.19mM); Clear solution
	此⽅案可获得 ≥ 0.71mg/mL (3.19mM，饱和度未知) 的澄清溶液，此⽅案不适⽤于实验周期在半个⽉以上的实验。以 1mL ⼯作液为例，取 100μL 7.1mg/mL 的澄清 EtOH 储备液加到 900μL ⽟⽶油中，混合均匀。
＜1mg/ml表示微溶或不溶。
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。

制备储备液

浓度溶液体积质量	1mg	5mg	10mg
1mM	4.4996mL	22.4982mL	44.9964mL
5mM	0.8999mL	4.4996mL	8.9993mL
10mM	0.4500mL	2.2498mL	4.4996mL
50mM	0.0900mL	0.4500mL	0.8999mL

生物活性

产品描述	cAMP和cGMP磷酸二脂酶的非专一性抑制剂。IBMX抑制了磷酸二脂酶，cAMP的增加激活了PKA，其结果是减少增殖，增加分化和诱发凋亡。IBMX抑制由苯肾上腺素诱导的色胺的减少。也作为腺苷受体拮抗剂。
靶点	PDE3 () 6.5μM	PDE4 () 26.3μM	PDE5 () 31.7μM
体外研究	At 100μM, KMUP-1 (a xanthine derivative) and IBMX are the most effective at inducing tracheal relaxation; the magnitude of the relaxation responses induced by KMUP-1 and IBMX are not significantly different. IBMX (100μM) activates renal outer medullary K+ (ROMK) channels (n=6, P<0.05) and prevents further channel activation by ANG II (n=6, P=NS) or cGMP. Of note is that pretreatment of cortical collecting duct (CCDs) isolated from high-K+ (HK)-fed rats with IBMX (100μM) for 20 min leads to a significant increase in tubular cAMP content to 1.43±0.35 pg/mm tubule length (n=14) compare with that measured in vehicle-treated controls (0.61±0.13 pg/mm tubule length, n=12, P<0.05)
体内研究	IBMX, a non-selective PDE inhibitor significantly decreases the liver glycogen storage (mg/g, IBMX 22±1.5 P<0.001). In comparison with the control group, IBMX and mc5 significantly increase plasma glucose (blood glucose,mg/dl, control=141±3, IBMX=210±17 P<0.01) while other test compounds (mc1, mc6, MCPIP and Win 47203) do not produce significant effect (control=141±3, mc1 160±7, mc6 175±9, MCPIP 179±8 and Win 47203 116±2 P>0.05) also mc2 does not change plasma glucose (control=141±3 and mc2=145±5). IBMX has the highest efficacy on increasing plasma glucose. Treatments with IBMX and Apocynin significantly decrease cold-induced elevation of right ventricular (RV) systolic pressure (23.5±1.8 and 24.2±0.6mMHg, respectively) although they do not decrease RV pressure to the warm control levels. IBMX or Apocynin significantly reduces medial layer thickness (19.0±0.9, and 16.9±0.8μM, respectively) and increases lumen diameter (62.7±4.2, and 59.5±4.3μM, respectively) of small PAs in cold-exposed rats

推荐实验方法(仅供参考)

Cell Assay

Cells are grown in 24-well plates 10⁵ cells per well. At confluence, monolayer cells are washed with phosphate buffer solution (PBS) and then incubated with KMUP-1 (0.1-100μM) in the presence of 100μM IBMX for 20 min. Incubation is terminated by the addition of 10% trichloroacetic acid (TCA). Cell suspensions are sonicated and then centrifuged at 2500× g for 15 min at 4°C. To remove TCA, the supernatants are extracted three times with 5 volumes of water-saturated diethyl ether. Then, the supernatants are lyophilized and the cyclic GMP or AMP of each sample is determined by using commercially available radioimmunoassay kits

Animal Administration

Mice

Male mice (25-35 g) are used. For the experiment, the test compound (IBMX, MCPIP, mc1, mc2, mc5 or mc6) or solvent (control) is injected subcutaneously to mice at 1mg/kg dosage twice a day (8:00 a.m. and 8:00 p.m.) for 7 days. Rats

Six groups of male Sprague-Dawley rats are used (150-180g, 6 rats/group). Three groups of rats are exposed to a climatecontrolled walk-in chamber maintained at moderate cold (5.0±1°C). The remaining groups are kept in an identical chamber maintained at room temperature (23.5±1°C, warm) and served as controls. After eight weeks of exposure to cold, 3 groups in each temperature condition received continuous IV infusion of IBMX (PDE-1 inhibitor, 8.5mg/kg/day), Apocynin (NADPH oxidase inhibitor, 25mg/kg/day) and vehicle (DMSO, 50%), respectively. The doses of drugs have been validated for effective inhibition of PDE-1 and NADPH oxidase activity, respectively. Body weight is measured weekly. After one week of drug infusion, the animals’ right ventricular systolic blood pressure (RVBP) is measured under anesthesia. The RVP is a reliable indicator of pulmonary arterial blood pressure (PAP) and has been used by numerous investigators for evaluating PH.

保存条件：

-20℃

UN码：

HazardClass：

危害声明：

安全说明：

点击下载核磁/氢谱图谱(PDF)

点击下载高效液相/气相图谱(PDF)

点击下载核磁/氢谱图谱(PDF)

搜索质检报告(COA)

参考文献 & 客户发表文献